Related Experiment Videos
HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis
W W Wilkerson1, E Akamike, W W Cheatham
1DuPont Merck Pharmaceutical Company, E500/3203 Experimental Station, Wilmington, Delaware 19880-0500, USA.
Journal of Medicinal Chemistry
|October 11, 1996
Summary
New cyclic urea 3-benzamides show potent inhibition against the human immunodeficiency virus (HIV) protease. These compounds may offer a new therapeutic strategy for treating Acquired Immunodeficiency Syndrome (AIDS).
Area of Science:
- Medicinal Chemistry
- Virology
- Drug Discovery
Background:
- Acquired Immunodeficiency Syndrome (AIDS) is a chronic, potentially life-threatening condition caused by the human immunodeficiency virus (HIV).
- HIV protease is a critical enzyme for viral replication, making it a key target for antiviral therapies.
Purpose of the Study:
- To synthesize and evaluate a novel series of N,N'-disubstituted cyclic urea 3-benzamides for their potential as HIV protease inhibitors.
- To investigate the antiviral activity of these compounds against HIV replication.
Main Methods:
- Chemical synthesis of N,N'-disubstituted cyclic urea 3-benzamide derivatives.
- Biochemical assays to determine HIV protease inhibition constants (Ki).
- Cell-based assays to measure inhibition of viral replication (IC90).
Main Results:
- Several synthesized benzamide derivatives demonstrated potent inhibition of HIV protease with Ki values below 0.050 nM.
- These compounds also exhibited strong antiviral activity, with IC90 values below 20 nM for viral replication.
- Quantitative structure-activity relationship (QSAR) analysis was performed to understand the molecular basis of inhibition.
Conclusions:
- The N,N'-disubstituted cyclic urea 3-benzamide series represents a promising class of compounds for HIV/AIDS treatment.
- The potent in vitro activity suggests these molecules warrant further investigation as potential anti-HIV drugs.
- Understanding the structure-activity relationships will guide the design of more effective inhibitors.